M. K. has received research grants from AstraZeneca and Boehringer Ingelheim; has served on advisory boards for AstraZeneca, Boehringer Ingelheim, Sanofi, Glytec, Novo Nordisk, ZS Pharma, Janssen, Merck (Diabetes) and Novartis; has served as a consultant for AstraZeneca, Boehringer Ingelheim, Sanofi, GSK, Janssen, Intarcia, Merck (Diabetes), Novo Nordisk, Glytec and ZS Pharma. K. I. B. has received grants to his institution from AstraZeneca for this study and fees for lectures and consulting from Novo Nordisk, Sanofi, Lilly, Boehringer Ingelheim and Merck Sharp & Dohme. M. A. C. has received personal fees from AstraZeneca, Merck, Sanofi‐Aventis, Chiesi and research support (non‐salary) from Abbott Laboratories, AstraZeneca, GlaxoSmithKline, The Medicines Company, Merck and Takeda. A. Z. F. has received grants from AstraZeneca and Merck and personal fees from Asclepius Analytics and Complete HEOR Solutions. J. P. W. has received lecture fees from Astellas, AstraZeneca, Boehringer Ingelheim, Janssen, Lilly, Novo Nordisk, Orexigen, Sanofi; has received consultancy (Institutional) fees from AstraZeneca, Boehringer Ingelheim, Janssen, Lilly and Orexigen; has received grants to his institution from Takeda, Novo Nordisk and AstraZeneca. K. K. has served as a consultant and speaker for AstraZeneca, Novartis, Novo Nordisk, Sanofi‐Aventis, Lilly, Merck Sharp & Dohme, Janssen and Boehringer Ingelheim; has received grants in support of investigator and investigator‐initiated trials from AstraZeneca, Novartis, Novo Nordisk, Sanofi‐Aventis, Lilly, Boehringer Ingelheim, Merck Sharp & Dohme and Roche; has served on advisory boards for Astra Zeneca, Novartis, Novo Nordisk, Sanofi‐Aventis, Lilly, Merck Sharp & Dohme, Janssen and Boehringer Ingelheim; is supported by the NIHR Collaboration for Leadership in Applied Health Research and Care East Midlands (CLAHRC EM). R. W. H. has received grants from AstraZeneca. A. N. has received personal fees from AstraZeneca for this study and honoraria for lectures and advisory board meetings from Novo Nordisk, Boehringer Ingelheim and Lilly. M. E. J. is a shareholder in Novo Nordisk; was employed by Steno Diabetes Center A/S, a research hospital within the Danish National Health Service and owned by Novo Nordisk A/S, until December 31, 2016; and has received grants from AstraZeneca. M. T. is an employee of Statisticon, which was under contract with AstraZeneca for this study. J. B., E. T. W., N. H. and P. F. are employees of AstraZeneca.
PubMed
